Efficacy and safety of fourth-generation CD19 CAR-T expressing IL7 and CCL19 along with PD-1 monoclonal antibody for relapsed or refractory large B-cell lymphoma

被引：0
|
作者：
俞腾
机构：
[1] Med Coll
[2] Zhejiang Univ
[3] Dept Hematol
[4] 2nd Affil Hosp
来源：
China Medical Abstracts(Internal Medicine) | 2024年 / 41卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R733.1 [网状内皮系统肿瘤];
学科分类号：
摘要：
Objective To explore the efficacy and safety of fourthgeneration chimeric antigen receptor T-cells (CAR-T),which express interleukin 7 (IL7) and chemokine C-C motif ligand 19 (CCL19) and target CD19,in relapsed or refractory large B-cell lymphoma.Methods Our center applied autologous 7×19 CAR-T combined with tirelizumab to treat 11 patients with relapsed or refractory large B-cell lymphoma.The efficacy and adverse effects were explored.
引用
收藏
页码：59 / 59
页数：1
相关论文
共 50 条
  • [31] A CD19/CD20-Directed Bispecific CAR-T Cell Therapy in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (NHL)
    Larson, Sarah M.
    Chen, Yvonne Y.
    Johnston, Jim
    Roy, Sylvain
    Patel, Pinakin
    Benjamin, Jonathan E.
    BLOOD, 2023, 142
  • [32] Timing of anti-PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma
    Hirayama, Alexandre V.
    Kimble, Erik L.
    Wright, Jocelyn H.
    Fiorenza, Salvatore
    Gauthier, Jordan
    Voutsinas, Jenna M.
    Wu, Qian
    Yeung, Cecilia C. S.
    Gazeau, Nicolas
    Pender, Barbara S.
    Kirchmeier, Delaney R.
    Torkelson, Aiko
    Chutnik, Abigail N.
    Cassaday, Ryan D.
    Chapuis, Aude G.
    Green, Damian J.
    Kiem, Hans -Peter
    Milano, Filippo
    Shadman, Mazyar
    Till, Brian G.
    Riddell, Stanley R.
    Maloney, David G.
    Turtle, Cameron J.
    BLOOD ADVANCES, 2024, 8 (02) : 453 - 467
  • [33] CD19 CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) - the Munich Real Life Experience
    Buecklein, V.
    Schmidt, C.
    Blumenberg, V.
    Reischer, A.
    von, Baumgarten L.
    Voelkl, A.
    Wagner, B.
    Humpe, A.
    Reilich, S.
    Bauer, M.
    Ostermann, H.
    Tischer, J.
    Stemmler, H-J.
    von Bergwelt, M.
    Subklewe, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 80 - 81
  • [34] Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma
    Tong, Chuan
    Zhang, Yajing
    Liu, Yang
    Ji, Xingyu
    Zhang, Wenying
    Guo, Yelei
    Han, Xiao
    Ti, Dongdong
    Dai, Hanren
    Wang, Chunmeng
    Yang, Qingming
    Liu, Wanli
    Wang, Yao
    Wu, Zhiqiang
    Han, Weidong
    BLOOD, 2020, 136 (14) : 1632 - 1644
  • [35] SAFETY AND EFFICACY COMPARISON OF HUMANIZED CD19 CAR-T VERSUS BLINATUMOMAB THERAPY FOR RELAPSED/REFRACTORY B-ALL PATIENTS
    Wang, Kexin
    Jiang, Songfu
    Hu, Yongxian
    Huang, He
    BONE MARROW TRANSPLANTATION, 2024, 59 : 199 - 200
  • [36] Phase 1/2 study of anbalcabtagene autoleucel, novel anti-CD19 CAR-T cell therapy with dual silencing of PD-1 and TIGIT in relapsed or refractory large B-cell lymphoma.
    Kim, Won Seog
    Kim, Seok Jin
    Yoon, Sangeun
    Kim, Jong Ran
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [37] Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy
    Iqbal, Madiha
    Jagadeesh, Deepa
    Chavez, Julio
    Khurana, Arushi
    Rosenthal, Allison
    Craver, Emily
    Epperla, Narendranath
    Li, Zhuo
    Isufi, Iris
    Awan, Farrukh T.
    Dholaria, Bhagirathbhai R.
    Maakaron, Joseph E.
    Sandoval-Sus, Jose D.
    Mishra, Rahul
    Saha, Aditi
    Annunzio, Kaitlin
    Bhaskar, Shakthi T.
    Sumransub, Nuttavut
    Fijalka, Andrew
    Ivanov, Stanislav A.
    Lin, Yi
    Kharfan-Dabaja, Mohamed A.
    BONE MARROW TRANSPLANTATION, 2024, 59 (02) : 211 - 216
  • [38] Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy
    Madiha Iqbal
    Deepa Jagadeesh
    Julio Chavez
    Arushi Khurana
    Allison Rosenthal
    Emily Craver
    Narendranath Epperla
    Zhuo Li
    Iris Isufi
    Farrukh T. Awan
    Bhagirathbhai R. Dholaria
    Joseph E. Maakaron
    Jose D. Sandoval-Sus
    Rahul Mishra
    Aditi Saha
    Kaitlin Annunzio
    Shakthi T. Bhaskar
    Nuttavut Sumransub
    Andrew Fijalka
    Stanislav A. Ivanov
    Yi Lin
    Mohamed A. Kharfan-Dabaja
    Bone Marrow Transplantation, 2024, 59 : 211 - 216
  • [39] PD-L1+ macrophage and tumor cell abundance and proximity to T cells in the pretreatment large B-cell lymphoma microenvironment impact CD19 CAR-T cell immunotherapy efficacy
    Hirayama, Alexandre V.
    Wright, Jocelyn H.
    Smythe, Kimberly S.
    Fiorenza, Salvatore
    Shaw, Akira N.
    Gauthier, Jordan
    Maloney, David G.
    Naresh, Kikkeri N.
    Yeung, Cecilia C. S.
    Turtle, Cameron J.
    HEMASPHERE, 2024, 8 (08):
  • [40] Prognostic significance of immune reconstitution following CD19 CAR T-cell therapy for relapsed/refractory B-cell lymphoma
    Stock, Sophia
    Bucklein, Veit L.
    Blumenberg, Viktoria
    Magno, Giulia
    Emhardt, Alica-Joana
    Holzem, Alessandra M. E.
    dos Santos, David M. Cordas
    Schmidt, Christian
    Griesshammer, Stefanie
    Frolich, Lisa
    Kobold, Sebastian
    von Bergwelt-Baildon, Michael
    Rejeski, Kai
    Subklewe, Marion
    HEMASPHERE, 2025, 9 (01):
12345